BioHarvest Sciences Inc.

Management's Discussion and Analysis

For the year ended December 31, 2021

(Expressed in U.S. dollars)

INTRODUCTION

The following Management Discussion and Analysis (”MD&A”) for BioHarvest Sciences Inc., together with its wholly owned subsidiaries ("BioHarvest Sciences” or “the Company”) prepared as of April 28, 2022 has been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Board (IASB). All amounts (other than per share amounts) are stated in U.S dollars rounded to the nearest thousand, unless otherwise indicated.

This MD&A should be read in conjunction with the audited consolidated financial statements of the Company (the “consolidated financial statements”) for the year ended December 31, 2021, and the related notes to those financial statements.

Statements in this report that are not historical facts are forward looking statements involving known and unknown risks and uncertainties, which could cause actual results to vary considerably from these statements. Readers are cautioned not to put undue reliance on forward looking statements.

The Company is publicly traded on the Canadian Securities Exchange under the symbol BHSC, on the OTC under the symbol CNVCF and on the Frankfurt Stock Exchange under the symbol 8MV. Continuous disclosure materials are available on our website at www.bioharvest.com.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This MD&A contains certain information that may constitute “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) which are based upon the Company’s current internal expectations, estimates, projections, assumptions and beliefs. Such statements can be identified by the use of forward-looking terminology such as "expect," “likely”, "may," "will," "should," "intend," or "anticipate", “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements included in this MD&A are made only as of the date of this MD&A. Forward-looking statements in this MD&A may include, but are not limited to, statements with respect to: a) licensing risks; b) regulatory risks; c) change in laws, regulations and guidelines; d) market risks; e) expansion of facilities; f) history of net losses; and g) competition. Certain of the forward-looking statements and forward-looking information and other information contained herein concerning the bio-farming, nutraceutical and cannabis industries, the general expectations of the Company concerning these industries and concerning the Company are based on estimates prepared by the Company using data from publicly available governmental sources, from market research and industry analysis and on assumptions based on data and knowledge of these industries, which the Company believes to be reasonable. While the Company is not aware of any misstatement regarding any industry or government data presented herein, the cannabis industry involves risks and uncertainties that are subject to change based on various factors and the Company has not independently verified such third party information. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company’s forward-looking statements are expressly qualified in their entirety by this cautionary statement. In particular, but without limiting the foregoing, disclosure in this MD&A under “Nature of the Business and Overview of Operations” as well as statements regarding the Company’s objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. See “Risk and Uncertainties” for further details. The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. You should not place undue reliance on forward- looking statements contained in this MD&A. The Company undertakes no obligation to update or revise any forward-looking statements.

Going Concern

Since inception through December 31, 2021, the Company has generated a cumulative loss of $60,134 thousands. For the year ended December 31, 2021, the Company generated negative cash flows from operating activities of $6,794 thousands and a loss in the amount of $10,256 thousands. As at the date of the issuance of these financial statements, despite a significant turn-around in the Company's revenue performance in its Israel operations as well as promising results from its VINIA® pilot launch in the USA, the Company has not generated significant enough sales, and therefore depends on financing activities from new and existing investors to fund its activities.

Management continues to evaluate the need for additional financing and is of the opinion that additional financing will be available to continue its planned activities in the normal course of business. Nonetheless, there is no assurance that the Company will be able to raise sufficient funds in the future to complete its planned activities. The foregoing indicates the existence of a material uncertainty that may cast substantial doubt as to whether the Company would continue as a going concern and realize its assets and settle its liabilities and commitments in the normal course of business. The Company’s consolidated financial statements have been prepared based on accounting principles applicable to a going concern, which assume the realization of assets and discharge of liabilities in the normal course of business.

NATURE OF BUSINESS AND OVERVIEW OF OPERATIONS

1. Summary

BioHarvest Sciences Inc. (the "Company" or "BioHarvest Sciences") was incorporated under the Business Corporations Act of British Columbia on April 19, 2013.

Corporate Structure



2. Overview of the business

The Company has developed a patented bio-cell growth platform technology which it has termed Bio-Plant CELLicitation ™ which enables the Company to grow, at industrial scale, the active and beneficial *ingredients* inherent in certain fruit and plants, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. The Company is currently focused on utilizing this technology platform which is protected by 14 patents covering two major verticals: Polyphenol/Antioxidants and Cannabis. The Company currently targets the Nutraceutical market with its first product in its polyphenol/anti-oxidant vertical called VINIA® and will shortly be targeting the Cannabis market with a range of Cannabis strains focused on the medicinal cannabis market

Polyphenol/Anti-Oxidants

The Company is engaged in research and development in the food industry. The Company's first Polyphenol/Anti-Oxidant products is a nutraceutical superfruit product called VINIA® which is a red grape powder that supplies the benefits of red wine consumption but without the sugar, calories and alcohol found in wine. The Company has conducted various clinical trials to verify the efficacy of the VINIA® powder and has made all required notifications required by the FDA to support the use of its claims on packaging and in communication materials. VINIA® has gone through the necessary regulatory approval processes both in the US and in Israel and is approved for classification as a food item as well as a dietary supplement/nutraceutical in these respective markets.

Cannabis

The Company is engaged in research and development of its Bio-Plant CELLicitation ™ technology for use in the cannabis industry and has finalized the research and development program for its first Cannabis products which it plans to bring to market in the next 6-12 months. This plant based technology produces cannabis trichomes which produce the key active cannabinoids, flavonoids and terpenes, in a process that is controlled, consistent, aseptic, non-GMO, and free of pesticides, solvents and pathogens.

The Company is focused on driving its growth in the multi-billion dollar nutraceutical and cannabis markets via its polyphenol/anti-oxidant and cannabis business verticals.

Polyphenol/Anti-Oxidants

The Company's first polyphenol/anti-oxidant nutraceutical superfruits product, VINIA®, is made of red grape (Vitis vinifera) cells grown in the Company's proprietary bioreactor facility. VINIA® is a fine dry pink-purple powder containing a matrix of polyphenols (with a high concentration of piceid resveratrol) in their natural state (as can be found in red wine), that have additive and synergistic benefits. The technology is protected by 14 granted patents. One of the main active ingredients in VINIA® is piceid resveratrol, maintaining the quality and inherent benefits present in nature without any solvent extraction or genetic modification. VINIA® is soluble when integrated with various liquids or cosmetics.

The Company has conducted several clinical trials at independent institutions (following rigorous protocols) to demonstrate that VINIA® is the first natural vasodilator produced without sugar or calories. VINIA®'s major mechanism of action is the increase of NOs (Nitric Oxidase) and decrease of ET1, an endothelial secreted protein, resulting in the vasodilation of blood vessels and blood perfusion. The following functional claims, supported by the clinical trials, clearly indicate the benefits of VINIA®:

- supports heart health by improving blood flow and delivery of oxygen;
- increases dilation of arteries and blood vessels;
- supports blood pressure already within normal range;
- supports blood circulation;

- improves physical energy and mental alertness via the delivery of increased blood flow and oxygen to the body's tissues and organs;
- fuels anti-oxidant activity with your veins and arteries;
- prevents oxidative damage to your cells ; and
- reduces oxidation of LDL cholesterol

The Company has also made all the required notifications required by the FDA to support the use of these claims on packaging and in communication materials.

VINIA® has gone through the necessary regulatory approval processes both in the US and in Israel. It has approval to be classified as a food item as well as a dietary supplement in these respective markets. The Company is also currently in the process of applying for regulatory approvals for the EU, UK and Canada.

The Company has invested over $50 million, primarily in R&D activities to support the business. This investment has enabled the Company to develop a disruptive technology platform which mirrors nature and allows it to efficiently produce plant cells that are identical to those that were originally sourced from the parent plant, ensuring optimal bio-availability and efficacy of the secondary metabolites and is termed Bio-Plant CELLicitation ™. In addition, our Bio-Plant CELLicitation™ technology is the only non GMO platform that can produce plant cells with significantly higher concentration of the active ingredients, as compared to those that are produced by nature as well as extremely high levels of solubility and bio-availability. Our technology provides a) consistent product production, b) a year round production cycle and c) products that are devoid of sugar, calories and contaminants such as pesticides, heavy metals and residues).

In terms of manufacturing capacity, the Company currently has a two tons/year production facility. The Company has signed a binding Memorandum of Understanding with Sugart Israel which will provide it with an additional capacity of 20 tons per year in order to meet expected demand from the market and drive significant cost reduction through economies of scale. This facility received Good Manufacturing Practice (GMP) approvals from the Israeli Ministry of Health in October 2021 as well as key ISO certifications. The Company completed the biological technology transfer in March 2022 and has already commenced growing VINIA® red grape cells at this new facility which will provide the Company with the required supply of product to scale the business further in H2 of 2022.

The Company has a well-developed innovation pipeline in its polyphenol/anti-oxidant vertical. Over the next three years, the Company plans to introduce a number of new products under the VINIA® brand including gummies and protein energy bars as well as introducing Olive cell based products and pomegranate cell based products using its Bio-Plant CELLicitation™ technology.

In Q4, 2020 the Company made a conscious decision to focus its sales and marketing efforts on direct to consumer channels and commenced a heavy online e-commerce marketing program for VINIA® to develop a significant and scalable direct-to-consumer e-commerce business in Israel. With a highly sophisticated and mature market, Israel can be regarded as a viable test market for

the Company as it seeks to optimize all aspects of the e-commerce marketing mix prior to scaling these activities in the USA market, which represents more than 40% of the global dietary supplement market.

Since launching this direct to consumer e-commerce marketing mix in Israel in November 2020, the Company has delivered average sales order revenues which exceed US $100 thousands per month. In Q4/2021 sales order revenues of VINIA ® reached an all-time high of US $501 thousands representing a 11% increase over Q3/2021 sales orders, and an 84% increase over Q3/2020. Full year 2021 sales orders for Israel were US $1.73 million representing a 325% year on year growth for the VINIA® Israel business.

The total number of VINIA® purchase orders in Q4/2021 achieved a new high of 2,583, an increase of 5% versus Q2/2021. It is important to point out that the Company has now increased its sales order revenues by 10% versus previous quarter for every quarter in 2021, demonstrating the continued positive growth momentum in the Israeli business. Further, the Company in Q4 continued to improve the overall mix of its available VINIA packages so as to increase the average order value to $USD 193 per customer per order.

The sales order results of $1.73 million for 2021 in the Israeli market, with its relatively small population of 9 million, enabled the Company to exceed US$ 1.6- 1.7 million per annum sales orders guidance range given on October 13, 2021, for 2021 projected sales orders in Israel. The consistent traction achieved by VINIA® demonstrates, in the opinion of management of the Company, recognition by the Israeli consumer of the quality and efficacy of VINIA®, and its position of being the only dietary supplement product containing piceid resveratrol from red grapes with high levels of solubility and bioavailability.

During Q4, 2021, the Company continue to accelerate its efforts in the Israeli market with the endorsement of VINIA® by Mordechai Shpigler, an Israeli football legend who holds the record of being the highest Israeli International goal scorer and who has achieved great fame and affection from the Israeli population and has appeal to VINIA®'s core consumer target of consumers aged 40 and over. This campaign has been successful in attracting new users to the VINIA franchise.

The accumulated knowledge and experience from the launch of VINIA® in the Israeli market has benefited the Company's pilot launch of VINIA® into the USA market. The Company commenced its U.S pilot program in mid May 2021. Sales orders in Q4-21 were $USD 325K, representing a 27% growth over Q3-21, with sales orders in December 2021 delivering a high of 117K. With >80% of sales being subscription packages generating monthly recurring revenue, $USD 75 average transaction spend and with 50% of customers being "repeat" customers, we are confident that we can build a scalable, sustainable, and profitable business.

The metrics are a good predictor of future demand in the U.S. for VINIA® where we anticipate significant growth in Q3 and Q4 of 2022 in line with the commencement of manufacturing at our new 20 Ton facility which commenced manufacturing of red grape cells in March 2022.

The Company continues to receive significant positive consumer reviews on its website and in social media forums on Facebook. To date the company has achieved a verified customer rating of 4.8/5 from over 600 verified reviews which demonstrates the efficacy of the product and the loyalty it is building with its consumer base. The Company in Q1 and Q2, 2022 will continue its efforts to build social trust in the product with the release of important influencer marketing programs showcasing the efficacy of the VINA® product with its consumers. In addition, the Company will continue to apply significant focus in Q1 and Q2 2022 from a USA perspective in continuing to optimize the e-commerce funnel and the marketing mix to support increased conversion rates at a lower cost of acquisition with the intent to significantly increase investment levels behind the brand in the 2nd half of 2022 as increased supply of VINIA® product comes on stream from the Company's new 20 ton per year VINIA® manufacturing facility.

To address the business-to business market, the Company signed an exclusive performance-driven distribution agreement with Batory Foods ("Batory"), a leading food ingredients distributor in the USA and one of the top three companies operating in the nutraceutical and beverage ingredient segments of the market. This agreement provides the Company with a best in class route-to-market for targeting major food, beverage, and nutraceutical companies, enabling it to effectively capture a significant share of the US $16 billion USA nutraceutical ingredients market focused on food, beverage, and dietary supplements. It will also allow the Company to address the fast growing US hemp-based CBD market with its focus on edible CBD.

In December 2020, Batory Foods, received the first order of VINIA® from "Designs for Health", a trusted source for health care professionals of research-backed health care nutritional products of superior quality. After a thorough review process, "Designs for Health" identified VINIA® as a key nutritional ingredient to utilize in its delivery of best-in-class science-based nutrition to its customers. VINIA has already been integrated into three unique new products under the "Designs for Health" branding ("NRF2 Modulator", "Senolytic Synergy" and "Bergavin™").

This strategic account is expected to deliver ongoing VINIA® product sales in the next 12 months as increased capacity of VINIA® becomes available from its new 20 ton per year manufacturing facility.

The Company continued to focus its efforts in Q4-21 on partnering further with Batory Foods to build partnerships with carefully selected major leadership companies in the food and nutraceutical markets. The Company now has the manufacturing capacity available to service the needs of these key strategic B2B customers. Accordingly, the Company initiated dialogue with key Companies in the USA who are well positioned in the health and wellness space, have premium brands with high unit economics which lead their respective segments and who have a purpose driven commitment to driving sustainability across all aspects of their business.
From a manufacturing perspective, the Company focused its efforts in Q4-21 on finalizing the completion of building its 20 ton per year new manufacturing facility and in implementing all the required protocols to drive full regulatory approval from the Israeli Ministry of Health.

On September 9th, the Company announced that this facility in Israel has successfully met the Israeli Ministry of Health's ISO9001 and ISO22000 (HACCP) certification requirements. The ISO9001 certification covers internationally recognized standards for quality assurance and management, and the ISO22000 (HACCP) certification ensures that the required quality control and quality management systems are in place across the end-to-end manufacturing process to ensure the highest product safety levels.

On November 22, the Company announced that the new manufacturing facility in Israel had obtained the GMP (Good Manufacturing Practices) certification from the Israeli Ministry of Health. The Company has now obtained all required certifications to commence manufacturing and to ensure that the factory employs the best practices in quality control and quality management systems across the end-to-end manufacturing process. The Company has focused significant resources over the past few months to complete the technology transfer process to the new facility and successfully commenced growing its red grape cells VINIA ® product at scalable levels in April this year so as to preparation for the scaling of its VINIA® business in the USA.

Cannabis

The Company continued its significant momentum in Q4-21 across its Cannabis development and commercialization program.

The Company announced in February 2021 that it is now able to consistently grow trichomes from multiple cannabis plant strains, in liquid media and has developed the unique know-how to optimize the growth performance of these cannabis trichomes in a predictable and highly efficient manner. Cannabis trichomes are the "natural factories" that produce the hundreds of distinct cannabinoids, terpenes and flavonoids in the cannabis plant, and their complex structure creates a major challenge for growing them in a liquid media. To date, no other company or academic group has, to our knowledge, publicly claimed to have successfully grown cannabis trichomes in liquid media.

This optimization of the trichome's growth is a key condition and major enabler for the consistent, cost efficient and sustainable production of plant-cell based cannabis and cannabinoids. The Company has achieved this ground-breaking milestone by leveraging its patented Bio-Plant CELLicitation ™technology, which is independent of any specific cannabis strain genetics. The Bio-Plant based CELLicitation™ technology produces cannabis cells in a process that is controlled, consistent, aseptic, non-GMO, and free of pesticides, solvents and pathogens.

In addition to announcing the above significant historical milestones in Q1-21, the Company in Q2-21 continued to make significant progress in its Cannabis commercialization program with the goal of bringing its first Cannabis product to market by H1, 2022.

In early June 2021 the Company announced it had achieved several critical milestones in the Bio-Plant CELLicitation™ of Cannabis and its Cannabis commercialization program including:

a. Developing the required baseline scientific measurement methods to be able to evaluate the level of cannabinoids in its unique composition of cells with trichomes.

b. Developing a unique configuration of cells with trichomes called “Bio-Tricho-Bubbles”. The Company’s “Bio-Tricho-Bubbles” have a unique appearance to regular trichomes on a Cannabis plant due to the fact that it leverages its Bio-Plant CELLicitation™ technology to grow trichomes at a higher density.
c. Optimizing the cannabinoid levels in its unique “Bio-Tricho-Bubbles”. For that purpose, a significant quantity of dedicated bioreactors is already in use producing cannabinoids.
d. Optimizing the drying process of these unique “Bio-Tricho-Bubbles” to minimize any potential damage to the trichome during the drying process.

In July 2021 the Company announced it had reached a significant milestone in its production of cannabinoids, with its first cell reservoir producing Cannabis trichomes (the natural micro-factories producing cannabinoids) for the past two years. This achievement demonstrates the efficiency and reliability of the Company’s Bio-Plant CELLicitation™ technology to produce the “flowering” stage of the Cannabis growth cycle at scale, which is significantly shorter, more productive, more cost-efficient, and more environmentally sustainable than conventional Cannabis cultivation. The issuer’s ground-breaking technology employs the original Cannabis plant and its respective cells as starting material only once, allowing the Company to harvest 13-17 cycles per year versus an average of 4 cycles per year for conventional Cannabis cultivation.

In August 2021 the Company announced its development of a groundbreaking “Amalgamated Trichomes Coral Structure” (ATCS) that it believes will enable it to revolutionize the production of Cannabis. The Company has successfully grown multiple trichomes in coral-shaped clusters where they are attached together in a natural structure. This structure protects the trichomes from the shear forces and guarantees much-needed mechanical stability during the growth process. This major advancement will allow the Company to quickly scale up its Cannabis production and assist in delivering its first cannabis product to market by H1, 2022

On September 1, 2021, the Company announced that it has successfully scaled its Cannabis cells with trichomes production by a factor of 250x and it is now growing Cannabis in medium-scale bioreactors, paving the way for its next scale-up milestone, where it will reach industrial-scale production. The next milestone, combined with the drying and measurement standards being concurrently developed, would constitute the successful completion of the Company’s Cannabis development program.

On Dec 8, 2021, the Company announced that it has produced a meaningful amount (10 kilograms) of full-spectrum Cannabis biomass at a commercial scale without growing the plant itself. This major milestone recorded the first time that any group – in either industry or academia – has successfully produced meaningful quantities of full-spectrum Cannabis biomass without growing the plant itself. The Cannabis biomass is not genetically modified and was produced using the Company’s proprietary Bio-Plant CELLicitation™ technology platform, which grows plant cells in their natural structure in proprietary bioreactors. The biomass consists of Cannabis cells, including Cannabis Trichome cells containing Cannabinoids such as CBD, THC and CBG, as well as other compounds that are naturally occurring in the Cannabis plant. The Company’s Cannabis

Trichome cells are amalgamated in a proprietary high-density coral-shaped structure, which enables a Trichome density (number of trichomes per unit surface) of up to 200 times greater than the conventional agriculture case.

On March 23, 2022, the Company announced the major milestone that it has produced Cannabis Biomass in large scale industrial bioreactors, which represents the completion of the Company's Cannabis R&D program. This milestone marks the start of the transition to commercial scale manufacturing. To that end, the Company has commenced the process to obtain a production license in Israel for its Cannabis products to complement the R&D license it has used to date for the Cannabis development program and plans to bring its first Cannabis products to market in H2 of 2022 and will be converting the current VINIA® 2 tons/year facility in Rehovot, Israel to produce Cannabis. This is happening in conjunction with the transition of all VINIA ® manufacturing to the new 20 tons/year facility in Yavneh, Israel, which will support the scaling of successful sales of VINIA® in the US and beyond.

Growing full spectrum, non-GMO Cannabis in Industrial scale bio-reactors without having to grow the plant is an unprecedented achievement by the Company and presents a great opportunity for the Cannabis industry and the Company. The Company now has the unique capabilities to produced consistent, clean, and efficacious Cannabis at scale that is produced with the highest ESG credentials and capital efficiency with significantly lower manufacturing costs, providing significant differentiation in the market due to the uniqueness of its value proposition to potential B2B partners and the end consumer. Accordingly, the Company has commenced partnership discussions with major Cannabis companies across multiple geographical jurisdictions (Israel, USA and Canada) as it assesses the optimal partnership and business model to bring its cannabis products to market.

Environmental, Social and Governance Reporting:

In June 2021 the Company announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report, detailing the Company's performance and ongoing commitment to creating a sustainable future. The Company a biotechnology company engaged in the production of Cannabis and cannabinoids to publish a comprehensive ESG report that commits to meaningful science-based targets over the next five years. Sustainability has always been at the core of the Company, with the Company's Bio-Plant CELLicitation™ technology allowing it to produce active plant ingredients without having to grow the plant itself. This practice substantially reduces resource requirements in general, as well as greenhouse gas emissions – which would otherwise be generated – and prevents biodiversity loss. For example, the Company in the production of its VINIA® product:

- Uses 99.99% less land than traditional agriculture
- Produces zero Scope 1 or direct GHG emissions in the Bio-Plant CELLicitation™ manufacturing process

- Uses no solvents or pesticides in the manufacturing process, resulting in wastewater that is 100% biodegradable and contains no chemicals
- Produces no hazardous waste in the manufacturing process

The report details the policies, metrics, and programs that support each of the Company's four key ESG pillars:

1. **Product:** Promoting pure well-being by providing fully traceable, science-based and innovative products with proven health benefits that improve the well-being of our customers.
2. **Process:** Demonstrating the minimal footprint of our production process while striving to reduce any adverse impact on water use, climate, and the environment.
3. **People:** Supporting our people by treating them with the utmost respect, the safest working conditions and allowing them to develop and thrive in the workplace; and
4. **Governance:** Setting the standard for end-to-end sustainability, ethical marketing, business ethics, and transparency in our industry.

The report is aligned with the United Nations Sustainable Development Goals and the reporting requirements of the Task Force on Climate-Related Financial Disclosures and the Sustainability Accounting Standards Board.

In the second half of this year, the Company plans to release its second ESG report which will focus on significant improvements made during its VINIA® manufacturing process as a result of moving to its new 20 ton facility as well as showcase the need to utilise significantly less resources to produce its Cannabis product when benchmarked versus other Cannabis Companies

Significant Developments

To better understand the Company's financial results, it is important to gain an appreciation of the significant events, transactions and activities that occurred during or have affected the period under review up to and including the date of this MD&A.

- On February 2, 2021, the Company completed a Private Placement financing by issuing 15,449,829 units at a price of CAD 0.40 ($0.32) per unit for gross proceeds of $4,865 thousands (CAD 6,180 thousands). Each unit consists of one common share of the Company and one non-transferable share purchase warrant. Each warrant will be exercisable to purchase an additional common share at a price of CAD 0.45 ($0.36) per share for a period of 12 months from closing of the private placement.

- On May 12, 2021, the Company launched its North American direct to consumer marketing programs for VINIA®

- In June 2021 the Company announced it had achieved a number of critical milestones in the Bio-Plant CELLicitation ™ of Cannabis as detailed above

- In August 2021 the Company announced its development of a groundbreaking Amalgamated Trichomes Coral Structure as detailed above

- On August 30, 2021, the Company completed a private placement financing by issuing 6,845,368 units at a price of CAD 0.45 ($0.36) per unit for gross proceeds of $2,431 (CAD 3,080). Net proceeds were $2,421 (CAD 3,067). Each unit consists of one common share of the Company and one half (1/2) of one share purchase warrant. Each warrant is exercisable to purchase an additional common share at a price of CAD 0.55 ($0.43) per share for a period of 12 months.

- On October 4, 2021, the Company completed a private placement financing by issuing 936,007 units at a price of CAD 0.45 ($0.36) per unit for gross proceeds of $331 (CAD 421). Net proceeds were $329 (CAD 418). Each unit consists of one common share of the Company and one half (1/2) of one share purchase warrant. Each warrant is exercisable to purchase an additional common share at a price of CAD 0.55 ($0.43) per share for a period of 12 months. The Company paid $2 (CAD 3) as finders' fees.

- During 2021 the Company issued 19,779,844 common shares as a result of the exercise of 15,192,446 warrants with an exercise price of CAD 0.23 ($0.17), the exercise of 3,106,386 warrants with an exercise price of CAD 0.3 ($0.23) and the exercise 1,481,012 warrants with an exercise price of CAD 0.15 ($0.11).

COVID-19

The continued global spread of COVID-19 could have an adverse impact on the business, operations and financial results of the Company, including with respect to challenges in finalizing the construction and installation of all equipment and systems required to fully operate the 20 Ton per year manufacturing facility at the end of Q3, 2021. The Company has already implemented a number of precautionary measures, which would not have otherwise been implemented prior to the COVID-19 outbreak, at its facility to ensure the safety of its personnel, and to potential clients and partners, which may adversely impact the Company's productivity from an R&D perspective and its business in the supply chain sector. The Company is also fully compliant with local rules and regulations instituted during COVID 19 and understands that mandatory or voluntary self-quarantines may limit the staffing at the Company's facility which will have a further impact on productivity. Management continues to be fully engaged in assessing the impact of COVID-19 and adjusting its operations accordingly to minimize the impact on business performance.

Amidst this highly challenging operating environment, the Company believes from a revenue generation perspective that COVID 19 pandemic has the potential ability to positively impact future revenue in Israel and in the USA. The COVID 19 pandemic has resulted in consumers having a

heightened awareness of the importance of taking all possible preventative actions to improve their overall cardio-vascular health. In addition, consumers have become more discerning in identifying products which are credible in delivering the benefits they seek and that are backed by appropriate scientific studies/clinical trials. Accordingly, the Company has seen continued increasing demand for its VINIA® product in Israel during the first nine months of its e-commerce launch and believes that the heightened focus of consumers on their overall health and wellness will continue to be a positive tail wind for the Israeli business and USA launch.

It is important to note that continued spread of COVID-19 globally could also lead to a deterioration of general economic conditions including a possible national or global recession. The Company believes that COVID-19 has had no material effect on its business, operations or financial results to date.

SELECTED INFORMATION

	Year ended December 31,		
	2021	**2020**	**2019**
	USD in thousands		
Revenues	**$ 2,102**	$ 396	218
Net (loss) and comprehensive (loss)	**$ (9,827)**	$ (6,584)	(5,310)
Basic and diluted (loss) per share	**(0.02)**	(0.019)	(0.05)

	Year ended December 31,		
	2021	**2020**	**2019**
	USD in thousands		
Total Assets	$ **10,208**	$ 5,304	$ 2,022
Total current liabilities	$ **2,923**	$ 1,894	$ 26,468
Total non-current liabilities	$ **4,430**	$ 5,705	$ 2,524

Year ended December 31, 2021, compared to the year ended December 31, 2020:

Our revenues, all of which relate to the Polyphenol Anti-Oxidant vertical of the Company, were $2,102 thousands for the year ended December 31, 2021, as compared to $396 thousands during the same period in the prior year. The increase in 2021 is a result of the Company's new business-to-consumer e-commerce strategy.

Our cost of revenues were $1,432 thousands for the year ended December 31, 2021, as compared to $258 thousands during the same period in the prior year. The increase is due to an increase in revenues during the period.

Our research and development expenses, which relate solely to our cannabis segment, were $4,129 thousands for the year ended December 31, 2021, as compared to $1,264 thousands during the same period in the prior year. The increase is mainly due to share based compensation expenses recorded in connection with options issued under the Company ESOP plan during the year ended December 31, 2021, the increase is also due to hiring of new employees and professional fees.

Our selling and marketing expenses relate to VINIA® and were $3,306 thousands for the year ended December 31, 2021, as compared to $467 thousands during the same period in the prior year. The increase was due to higher spend on marketing as part of the Company's new business-to-consumer e-commerce strategy in Israel. The marketing expenses also includes the associated marketing start-up costs for the Q2 launch of VINIA® in the USA.

Our general and administrative expenses decreased to $2,155 thousands for the year ended December 31, 2021, as compared to $3,974 thousands during the same period in the prior year. The decrease is mainly due to decrease in the Company's Liability to Agricultural Research Organization.
Our general and administrative expenses are incurred to support both our business segments.

Our listing expenses were $Nil for the year ended December 31, 2021, as compared to $599 during the same period in the prior year. The listing expenses are due to the Merger Transaction that closed on March 31, 2020.

Our finance expenses were $1,626 thousands for the year ended December 31, 2021, as compared to $611 thousands during the same period in the prior year. The main increase is due to fair value adjustments of the Company's outstanding warrants and accrued interest on the Liability to Agricultural Research Organization.
Our finance expenses are incurred to support both our business segments.

Our finance incomes were $291 thousands for the year ended December 31, 2021, as compared to $193 thousands during the same period in the prior year.
Our finance incomes are incurred to support both our business segments.

Summary of Quarterly Results

The following represents the summarized quarterly financial results for the past eight quarters:

	December 31, 2021	September 30, 2021	June 30, 2021	March 31, 2021
	USD in thousands			
Total Revenue for the period	730	644	415	313
Net income (loss) before income taxes for the period	(1,753)	(3,044)	1,779	(6,809)
Net income (loss) for the period	(1,753)	(3,044)	1,779	(6,809)
Net income (loss) for the period per share	(0.00)	(0.01)	0.00	(0.02)

	December 31, 2020	September 30, 2020	June 30, 2020	March 31, 2020
	USD in thousands			
Total Revenue for the period	262	53	39	42
Net (loss) before income taxes for the period	(3,098)	(1,844)	(1,370)	(272)
Net (loss) for the period	(3,098)	(1,844)	(1,370)	(272)
(Loss) per share for the period	(0.007)	(0.005)	(0.008)	(0.003)

Financial instruments and risk management

The Company is exposed to a variety of financial risks, which results from its financing, operating and investing activities. The objective of financial risk management is to contain, where appropriate, exposures in these financial risks to limit any negative impact on the Company's financial performance and position. The Company's financial instruments are its cash, trade and other receivables, trade payables, lease liabilities, ARO liability and other liabilities. The main purpose of these financial instruments is to raise finance for the Company's operation. The Company actively measures, monitors and manages its financial risk exposures by various functions pursuant to the segregation of duties and principals. The risks arising from the Company's financial instruments are mainly currency risk and liquidity risk. The Company has no interest rate risk as the balances exposure to interest is minimal. The risk management policies employed by the Company to manage these risks discussed below.

Foreign currency risk:

Foreign exchange risk arises when the Company enters into transactions denominated in a currency other than its functional currency. The Company is exposed to currency risk to the extent that there is a mismatch between the currency in which it denominated and the respective functional currency of the company.

The currencies in which some transactions are primarily denominated are CAD, US dollars and NIS.

The Company's policy is not to enter into any economic hedging transactions to neutralize the effects of foreign currency fluctuations.

Liquidity and Capital resources

The consolidated financial statements have been prepared on a going concern basis whereby the Company is assumed to be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern assumption was not appropriate for the consolidated financial statements, then adjustments of a material nature would be necessary in the carrying value of assets such as property and equipment, liabilities, the reported expenses, and the balance sheet classifications used. Management continues to pursue financing opportunities for the Company to ensure that it will have sufficient cash to carry out its planned programs beyond the next year.

At December 31, 2021 the Company had cash of $4,117 thousands (December 31, 2020 $1,783 thousands). The Company had current assets of $5,665 (December 31, 2020 $2,237) and current liabilities of $2,923 thousands (December 31, 2020 - $1,894 thousands). At December 31, 2021, the Company's working capital was $2,742 thousands (December 31, 2020–$343 thousands).
During the year ended December 31, 2021, the Company's overall position of cash and cash equivalents increased by $2,338 thousands. (December 31, 2020- $878 thousands). This change in cash held can be attributed to the following:

- The Company's net cash used in operating activities during the year ended December 31, 2021 was $6,794 thousands as compared to net cash used of $3,875 thousands for the year ended December 31, 2020. The amount is primarily a result of the losses incurred in the operations of the Company.
- Cash used in investing activities for the year ended December 31, 2021 was $1,640 thousands as compared to cash used of $173 thousand for the year ended December 31, 2020. The amount used in 2021 and 2020 relates primarily to the purchase of property, plant and equipment.
- Cash generated from financing activities during the year ended December 31, 2021, was $10,772 thousands as compared to $4,926 thousands from financing activities for the year ended December 31, 2020. The cash generated in 2021 and 2020 is primarily from the proceeds received from private placements and exercise of warrants.

Since the Company will not be able to generate cash from its operations in the foreseeable future, the Company will have to rely on the issuance of shares or the exercise of options, warrants and loans to fund ongoing operations and investment. The ability of the Company to raise capital will depend on market conditions and it may not be possible for the Company to issue shares on acceptable terms or at all.

Off Balance Sheet Agreements

The Company has not entered into any material off-balance sheet arrangements such as guarantee contracts, contingent interests in assets transferred to unconsolidated entities, derivative financial obligations or arrangements with respect to any obligations under a variable interest equity arrangement.

Transactions with Related Parties

The Company's key management personnel have the authority and responsibility for overseeing, planning, directing and controlling the activities of the Company. Key management personnel include members of the Board of Directors, the Chief Executive Officer and the Chief Financial Officer. Compensation earned by key management for the year ended December 31, 2021 was as follows:

1. **Related party transactions:**

For the year and period ended December,	2021	2020
Compensation of key management personnel of the Company:		
CEO Management fees	462	330
Chairman Management fees	253	136
CFO Management fees	30	19
Share base payment to CEO	315	451
Share base payment to Chairman	565	250
Other related party transactions:		
Share base payments	298	403

2. **Balance with related parties:**

As of December 31 ,	2021	2020
Due to CEO	70	53

Critical Accounting Estimates

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses.

The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis.

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

1. Share based compensation

   The Company has a share based compensation plan for its employees. The estimated fair value of share options is determined using the Black Scholes model. Inputs to the model are subject to various estimates related to volatility, interest rates, dividend yields and expected life of the stock options issued. Fair value inputs are subject to market factors, as well as internal estimates.

2. Derivative liability – Warrants

   The Company uses the Black-Scholes option-pricing model to estimate fair value at each reporting date. The key assumptions used in the model are the expected future volatility in the price of the Company's shares and the expected life of the warrants. Significant estimates used in the preparation of the consolidated financial statements include but are not limited to stock based compensation and future income taxes.

3. Liability to Agricultural Research Organization

   The Company measures the liability to Agricultural Research Organization, each period, based on discounted cash flows derived from Company's future anticipated revenues. The discount rate reflects the market rate.

4. Determining the transaction price and amounts allocated to the performance obligations

   In transactions with customers that include variable consideration, the Company assesses, based on past experience, business forecasts and current economic conditions, whether it is highly probable that a significant reversal in the amount of revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

   In determining the transaction price for each contract with a customer, the Company considers the effect of the right of return.

The Company also assesses for each transaction with variable consideration the approach that will best reflect the amount of the consideration to which the Company will be entitled, using either the "expected value" method or the "most likely amount" method.

Common Share Data

As at the date of this MD&A, the Company had the following securities issued and outstanding:

Type of Security	Number Outstanding
Common shares	454,178,636
Stock options	63,915,113
Warrants	22,487,988

Investor Relations Contracts

There are no investor relations contacts outstanding.

Contractual Obligations

The Company has no contractual obligations that have not been disclosed.

Risks and Uncertainties

Market Risks. The Company's securities trade on public markets and the trading value thereof is determined by the evaluations, perceptions and sentiments of both individual investors and the investment community taken as a whole. Such evaluations, perceptions and sentiments are subject to change, both in short term time horizons and long term time horizons. An adverse change in investor evaluations, perceptions and sentiments could have a material adverse outcome on the Company and its securities.

Financing Risks. The Company will be dependent on raising capital through a combination of debt and/or equity offerings. There can be no assurance that the capital markets will remain favorable in the future, and/or that the Company will be able to raise the financing needed to continue its business at favorable terms, or at all. Restrictions on the Company's ability to finance could have a material adverse outcome on the Company and its securities.

Share Price Volatility and Price Fluctuations. In recent years, the securities markets in Canada have experienced a high level of price and volume volatility, and the market prices of securities of many corporations have experienced wide fluctuations which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies. Such volatility has been particularly evident with regards to the share price of medical cannabis companies, which are public issuers in Canada.

Key Personnel Risks. The Company's efforts are dependent to a large degree on the skills and experience of certain of its key personnel, including the board of directors. The Company does not maintain "key man" insurance policies on these individuals. Should the availability of these persons' skills and experience be in any way reduced or curtailed, this could have a material adverse outcome on the Company and its securities.

General Business Risk and Liability. Given the nature of the Company's business, it may from time to time be subject to claims or complaints from investors or others in the normal course of business. The legal risk facing the Company, its directors, officers and employees in this respect include potential liability for violations of securities laws, breach of fiduciary duty or misuse of investors' funds. Some violations of securities laws and breach of fiduciary duty could result in civil liability, fines, sanctions or the suspension or revocation of the Company's right to carry on its existing business. The Company may incur significant costs in connection with such potential liabilities.

Competition. There is potential that the Company will face intense competition from other companies, some of which can be expected to have more financial resources, industry, manufacturing and marketing experience than the Company. Additionally, there is potential that the industry will undergo consolidation, creating larger companies that may have increased geographic scope and other economies of scale. Increased competition by larger, better-financed competitors with geographic or other structural advantages could materially and adversely affect the business, financial condition and results of operations of the Company. To remain competitive, the Company will require a continued level of investment in research and development, marketing, sales and client support. The Company may not have sufficient resources to maintain research and development, marketing, sales and client support efforts on a competitive basis which could materially and adversely affect the business, financial condition and results of operations of the Company.

Regulation of the Cannabis Industry. The cannabis related business of the Company are heavily regulated in all jurisdictions where it carries out its business. The Company's operations are subjected to various laws, regulations and guidelines by governmental authorities, relating to the manufacturing, marketing, management, transportation, storage, sale, pricing and disposal of medical cannabis, and also including laws and regulations relating to health and safety, insurance coverage, the conduct of operations and the protection of the environment.

The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by governmental authorities. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and could have a material adverse effect in the business, results of operations and financial condition of the Company.

Failure to comply with the laws and regulations applicable to its operations may lead to possible sanctions including the revocation or imposition of additional conditions on licenses to operate the

Company's business, the suspension or expulsion from a particular market or jurisdiction or of its key personnel, and the imposition of fines and censures. To the extent that there are changes to the existing laws and regulations or the enactment of future laws and regulations that affect the sale or offering of the Company's products or services in any way, this could have a material adverse effect on the business, results of operations and financial condition of the Company.

Reliance on Key Business Inputs. The Company's business is dependent on a number of key inputs and their related costs including raw materials and suppliers related to its growing operations as well as electricity, water, and other utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition and operating results of the Company. Any liability to secure required supplies and services or to do so on appropriate terms could also have a materially adverse impact on the business, financial condition, and operating results of the Company.

Potential product recalls. Manufacturers and distributers of products are sometimes subjected to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packing safety and inadequate or inaccurate labeling disclosers. If the Company's product is recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expenses of the recall and any legal proceedings that might arise in connection with the recall.

The Company may lose a significant number of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention.

Although the Company had detailed procedures in place for testing finished products, there can be no assurance that any quality, potency or contamination problem will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuit. Additionally, if one of the Company's product was subjected to recall, the image of the Company could be harmed. A recall for any one of the foregoing reasons could lead to decreased demand for the Company's products and could have a material adverse effect on the results of operations and financial condition of the Company.

History of Net Losses; Accumulated Deficit; Lack of Revenue from Operations. The Company has incurred net losses to date. The Company may continue to incur losses. There is no certainty that the Company will operate profitably or provide a return on investment in the future.

Uninsurable risks. The Company may become subject to liability for events, against which it cannot insure or against which it may elect not to insure. Such events could result in substantial damage to property and personal injury. The payment of any such liabilities may have a material, adverse effect on the Company's financial position.

No History of Dividends. Since incorporation, the Company has not paid any cash or other dividends on its common stock and does not expect to pay such dividends in the foreseeable future, as all available funds will be invested primarily to finance the Company's operations. The Company will need to achieve profitability prior to any dividends being declared.

OTHER INFORMATION

Additional information related to the Company, is available for viewing on SEDAR at **www.sedar.com**.